This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases, evaluated the safety and effectiveness of olipudase alfa in children with acid sphingomyelinase deficiency (ASMD) over two years. Researchers monitored side effects and assessed improvements in ASMD symptoms by measuring lung and liver function, liver and spleen size, blood lipid levels, and growth.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results’ and was published in the Orphanet Journal of Rare Diseases.

Visit BMC using the link to read the original article.